



Scheduled Presentations at the 2023 ASTRO Meeting

Scheduled event times listed in Pacific Standard Time. All rooms listed are in the San Diego Convention Center.

Saturday, September 30

Varian/Siemens User Meeting
Improving RT Segmentation with Dual Energy CT
(**Jess Miller**), 5 PM, Hilton San Diego Bayfront, Indigo Ballroom-Level 2

Sunday, October 1

Scientific Session
Normal Tissue Injury and Dose Rate Effects
(**Pippa Cosper**, Moderator), 8 AM, Room 32

Advancement in Imaging for Radiation Oncology
Panel 02
Dual Energy CT Application in Radiation Therapy
(**Jess Miller**), 8:00 AM (8:32 AM), Room 29

Lung Cancer and DEIH
Poster Q&A
Longitudinal Radiomics-Based Prediction of Local Recurrence after Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
(**Manlu Liu**), 4:45 PM, Hall B2, Screen 16

Monday, October 2

Radiation and Cancer Physics
Quick Pitch
Segmentation
(**Carri Glide-Hurst**, Moderator), 8 AM, Room 8

www.humonc.wisc.edu @UW_RadoncDHO

Central Nervous System and Palliative Care
Poster Q&A
Leveraging Quantitative Imaging and Machine Learning to Differentiate Radionecrosis from Disease Recurrence in Patients with Brain Metastases
(**Mustafa Basree**), 10:45 AM, Hall B2, Screen 2

Pulsed Reduced Dose Rate Re-Irradiation for Recurrent Grade 4 Gliomas: A Retrospective Analysis of Safety and Efficacy
(**Brett Morris**), 10:45 AM, Hall B2, Screen 23

Immune Checkpoint Inhibition (ICI): Incorporation Into SCLC Management; Impacts on Toxicity for LA-NSCLC
Quick Pitch
Treatment Efficacy Outcomes Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Survival Analysis of a Phase IB Trial
(**Brett Morris**), 5:00 PM (5:20 PM), Room 8

Tuesday, October 3

Keynote Address
Random Acts of Medicine
(**Hari Menon**), 9:15am, Ballroom 20

Special Session
Awards Ceremony
(**Paul Harari**), 10:15 AM, Ballroom 20

Gastrointestinal Cancer and Sarcoma
Poster Q&A
Neoadjuvant Stereotactic MR-Guided Ablative Radiation Therapy (SMART) and Surgical Outcomes in Patients with Pancreatic Cancer
(**Hari Menon**), 12:45 PM, Hall B2, Screen 19

Genitourinary Cancer, Patient Safety, and Nursing
Poster Q&A
Disease and Toxicity Outcomes after Salvage Radiotherapy (SRT) for Biochemically Recurrent Prostate Cancer (PC) for Patients Enrolled in a Phase II, Open Label Trial Investigating Neoadjuvant Chemohor
(**Graham Campbell**), 2:30 PM, Hall B2, Screen 3

Empowering the Role of Nurse Triage in Radiation Oncology – A Single Center Analysis
(**Colin Harari**), 2:30 PM, Hall B2, Screen 11

Evaluation of kV Triggered Fiducial Tracking for Prostate SBRT Intrafraction Motion Management
(**Colin Harari**), 2:30 PM, Hall B2, Screen 11

Factors Associated with Grade 3-4 Late Toxicity after Hypofractionated Prostate Salvage Radiation
(**Kaili Ranta**), 2:30 PM, Hall B2

Immunotherapy and Immune Response
Scientific Session
Discussant
(**Zachary Morris**), 2:30 PM (3:30 PM), Room 2

Evolving Roles of Medical Physicists in Clinical Trials
Education Session
Adapting to the Evolving Technologies in Clinical Trials
(**Carri Glide-Hurst**), 2:30 PM (3:08 PM), Room 29

Hematologic Malignancies and Digital Health Innovation
Poster Q&A
Combining obinutuzumab with Radiation for Treatment Refractory Diffuse Large B Cell Lymphoma: Retrospective Safety and Efficacy Analysis
(**Brett Morris**), 4:00 PM, Hall B2, Screen 10

Radiotherapy Evolution, Prognostication and Outcomes in Soft Tissue Sarcoma

Quick Pitch

Initial Results of a Phase II Trial of Hypofractionated Radiation Therapy for Inoperable Soft Tissue Sarcoma
(Bradley Eckelmann), 4:00 PM (4:10 PM), Room 5

Tumor and Radiation Biology

Quick Pitch

Mitotic Errors Increase Radiation Sensitivity in Multiple Cancer Cell Types and in Laryngeal Cancer Patients
(Pippa Cospers), 4:00 PM (4:25 PM), Room 8
**Best Abstract in Biology Recipient*

Radiobiology-Guided Innovations in the Integration of Radiation and Immunotherapies

Education Session

The Effects of Radiation Dose, Dose-Rate, and Dose Heterogeneity on Anti-Tumor Immune Response
(Zachary Morris), 4:00 PM (4:36 PM), Room 33

Innovative Approaches to Individualizing Therapy for Head & Neck and Skin Cancer

Quick Pitch

A Pilot, First in Human Study of Autologous IFN-Gamma Stimulated Mesenchymal Stromal Cells for Treatment of Radiation Induced Xerostomia
(Grace Blitzer), 5:15 PM (5:35 PM), Room 4

Wednesday, October 4